




The relative strengths and weaknesses of Nurix Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Nurix Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 29% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	295,503
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	86,958
Liabilities, Non-Current	68,147
Other Assets	43,287
Other Compr. Net Income	3,664
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	88,102
Property and Equipment	16,808
Research and Development	189,148
Selling, General and Administrative Expense	42,902

Output Variable	Value in 1000 USD
Assets	355,598
Liabilities	155,105
Expenses	232,050
Revenues	88,102
Stockholders Equity	200,493
Net Income	-143,948
Comprehensive Net Income	-142,116
BaseVar	417,260
ECR before LimitedLiability	116%
Economic Capital Ratio	242%